Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence

• Authors: Susanne P. Stoof, National Institute of Public Health and the Environment; Mariëtte B. van Ravenhorst, National Institute of Public Health and the Environment; Debbie M. van Rooijen, National Institute of Public Health and the Environment; Richarda M. de Voer, Radboud University Medical Center; Fiona R. M. van der Klis, National Institute of Public Health and the Environment; Greet J. Boland, University Medical Centre Utrecht; Elisabeth A. M. Sanders, National Institute of Public Health and the Environment; Guy A. M. Berbers, National Institute of Public Health and the Environment; Peter Teunis, Emory University
• Journal Title: Clinical and Vaccine Immunology
• Volume: Volume 24, Number 2
• Publisher: American Society for Microbiology | 2017-02, Pages e00429-16-e00429-16
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1128/CVI.00429-16
• Subjects: Biology, Virology; Health Sciences, Immunology; Biology, Microbiology
• Keywords: Neisseria meningitidis; Adolescent; Meningococcal serogroup C conjugate vaccine; Long-term; Antibodies

Abstract

Adolescent vaccination is now considered the key factor for offering direct protection against meningococcal disease but also for reducing carriage and transmission and, in this way, establishing herd protection. This study estimated age-dependent patterns in functional meningococcal serogroup C (MenC) antibody kinetics after primary MenC conjugate (MenCC) vaccination in adolescents. Serum samples (n = 1,676) were drawn from 2006 to 2011 from individuals aged 9 to 18 years at the time of primary MenCC vaccination in 2002. Functional antibody levels were measured with a serum bactericidal antibody assay (SBA) using rabbit complement. SBA titers gradually declined with time. Up to 9 years after primary vaccination, SBA titers were estimated to be higher in individuals who were aged 13 to 18 years at priming than in those who were aged 9 to 10 years at priming. Based on a linear mixed model, the higher functional antibody levels with age seem to be due to the achievement of higher peak levels upon vaccination rather than to lower rates of decline. It is estimated that 35 to 50% of individuals who received a single primary MenCC vaccination at an age of 9 to 18 years in 2002 will still have sufficient protective antibody levels 15 years later. Using a linear mixed model based on cohort data for a single dated serum sample per person, we were able to estimate the level of protection against MenC up to 15 years after a single vaccination. The current study shows that analysis of antibody kinetics can be done using cross-sectional serology data and is therefore relevant for future serosurveillance studies.